Ian E. James
GlaxoSmithKline
44 Papers
605 Citations
Ian E. James is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Osteoclast & Cathepsin K. The author has an hindex of 30, co-authored 44 publications.
Chat about Author
Papers
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
John Emery,Peter C. McDonnell,Michael Brigham Burke,Keith Charles Deen,Sally D. Lyn,Carol Silverman,Edward Dul,Appelbaum Edward Robert,Chris Eichman,Rocco DiPrinzio,R.A. Dodds,Ian E. James,Martin Rosenberg,John C. Lee,Peter Young +14 more
TL;DR: A fifth TRAIL receptor is identified, namely osteoprotegerin (OPG), a secreted tumor necrosis factor receptor homologue that inhibits osteoclastogenesis and increases bone density in vivo and is suggested to suggest potential cross-regulatory mechanisms by OPG and TRAIL.
1.3K
Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.
Fred H. Drake,R.A. Dodds,Ian E. James,Janice R. Connor,Christine Debouck,Susan B. Richardson,Elizabeth Lee-Rykaczewski,Lindsay Coleman,David J. Rieman,Ray Barthlow,Gregg A. Hastings,Maxine Gowen +11 more
TL;DR: The abundant expression of cathepsin K selectively in osteoclasts strongly suggests that it plays a specialized role in bone resorption and suggests that random sequencing of ESTs from cDNA libraries is a valuable approach for identifying novel cell-selective genes.
758
Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats
Maxine Gowen,George B. Stroup,R.A. Dodds,Ian E. James,Bart J. Votta,Brian R. Smith,Pradip K. Bhatnagar,Lago Amparo M,James F. Callahan,Eric G. Delmar,Michael A. Miller,Edward F. Nemeth,John Fox +12 more
TL;DR: It is demonstrated that an increase in endogenous PTH secretion, induced by antagonism of the parathyroid cell Ca(2+) receptor with a small molecule, leads to a dramatic increase in bone turnover, and it is suggested that a novel approach to the treatment of osteoporosis is suggested.
295
Peptide Aldehyde Inhibitors of Cathepsin K Inhibit Bone Resorption Both In Vitro and In Vivo
Bartholomew J. Votta,Mark Alan Levy,Alison M. Badger,Bradbeer Jeremy N,R.A. Dodds,Ian E. James,Scott K. Thompson,Mary J. Bossard,Thomas Joseph Carr,Janice R. Connor,Thaddeus A. Tomaszek,Lawrence Szewczuk,Fred H. Drake,Daniel F. Veber,Maxine Gowen +14 more
TL;DR: Inhibitors of cathepsin K are effective at reducing osteoclast‐mediated bone resorption and may have therapeutic potential in diseases of excessive bone Resorption such as rheumatoid arthritis or osteoporosis.
208
Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone.
R.A. Dodds,Janice R. Connor,Ian E. James,Elizabeth Lee Rykaczewski,Appelbaum Edward Robert,Edward Dul,Maxine Gowen +6 more
TL;DR: This study characterized expression of osteopontin mRNA and protein expression in both intramembranous and endochondral ossification, as well as remodeling bone, in the human osteophyte and confirmed that osteoclasts are responsible for the deposition of osteOPontin in vitro.
192